Konstantinos Votanopoulos to Drug Screening Assays, Antitumor
This is a "connection" page, showing publications Konstantinos Votanopoulos has written about Drug Screening Assays, Antitumor.
Connection Strength
1.638
-
Votanopoulos KI, Forsythe S, Sivakumar H, Mazzocchi A, Aleman J, Miller L, Levine E, Triozzi P, Skardal A. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study. Ann Surg Oncol. 2020 Jun; 27(6):1956-1967.
Score: 0.687
-
Votanopoulos KI, Mazzocchi A, Sivakumar H, Forsythe S, Aleman J, Levine EA, Skardal A. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study. Ann Surg Oncol. 2019 Jan; 26(1):139-147.
Score: 0.636
-
Forsythe S, Mehta N, Devarasetty M, Sivakumar H, Gmeiner W, Soker S, Votanopoulos K, Skardal A. Development of a Colorectal Cancer 3D Micro-tumor Construct Platform From Cell Lines and Patient Tumor Biospecimens for Standard-of-Care and Experimental Drug Screening. Ann Biomed Eng. 2020 Mar; 48(3):940-952.
Score: 0.164
-
Mazzocchi AR, Rajan SAP, Votanopoulos KI, Hall AR, Skardal A. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening. Sci Rep. 2018 02 13; 8(1):2886.
Score: 0.151